PRADAXA 150 mg twice daily provided an additional 35% risk reduction of stroke/systemic embolism vs warfarin
- Superior reduction of ischemic and hemorrhagic stroke vs warfarin
- Similar rate of major bleeds‡ with PRADAXA vs warfarin
- PRADAXA is the ONLY anticoagulant to demonstrate superior reduction of ischemic stroke vs warfarin
- PRADAXA also demonstrated a lower rate of intracranial bleeding vs warfarin
Additional 35% risk reduction of stroke/systemic embolism vs warfarin. Protect the brain by reducing the risk of ischemic stroke.
Learn more at pradaxapro.com